



The Drug Utilization Review Board Reviewed the Following New Drugs and Classes on September 20, 2012

The Georgia Medicaid Fee-for-Service (FFS) Drug Utilization Review (DUR) Board has conducted its clinical and financial evaluations and provided its recommendations for the Department of Community Health's (DCH) final decisions on the following new drugs and classes for the Georgia Medicaid FFS Preferred Drug List (PDL). The current PDL is located at <http://dch.georgia.gov/pharmacy> under the Preferred Drug Lists link or directly at http://dch.georgia.gov/00/channel_title/0,2094,31446711_32050640,00.html.

New Drug Reviews

Long-Acting Beta-Agonist

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Arcapta*[™].

Antineoplastics

The DUR Board recommended *Preferred* status with *Prior Authorization* for *Erivedge*[™] and *Inlyta*[™].

Respiratory Agent

The DUR Board recommended *Preferred* status with *Prior Authorization* for *Kalydeco*[™].

Anticonvulsant

The DUR Board recommended *Preferred* status with *Prior Authorization* for diagnosis, trial of clonazepam and trial of one other agent for Lennox-Gastaut Syndrome for *Onfi*[™].

Topical Antineoplastics

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Picato*[™]. The DUR Board also recommended *Non-Preferred* status with *Prior Authorization* for *Zyclara*[®].

Topical Anorectal

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Rectiv*[™].

Ophthalmic Prostaglandin

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Zioptan*[™].

Class Reviews

Antihyperkinesia Agents

The DUR Board recommended *No Changes* from the current PDL status.



Long-Acting Beta-Agonist Inhalers

The DUR Board recommended *No Changes* from the current PDL status.

Statins

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Crestor*[®] and *No Changes* from the current PDL status for all other agents.